Nuvectra (NASDAQ:NVTR) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also recently issued reports about the company. Zacks Investment Research cut Nuvectra from a “buy” rating to a “hold” rating in a research report on Wednesday, August 29th. JMP Securities upped their price objective on Nuvectra from $18.00 to $23.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Nuvectra in a research report on Wednesday, August 8th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Nuvectra presently has a consensus rating of “Buy” and an average target price of $23.50.

NVTR stock opened at $21.39 on Friday. The company has a market capitalization of $376.66 million, a P/E ratio of -5.07 and a beta of -0.34. Nuvectra has a 12-month low of $7.60 and a 12-month high of $25.17. The company has a current ratio of 7.63, a quick ratio of 3.77 and a debt-to-equity ratio of 0.42.

Nuvectra (NASDAQ:NVTR) last released its quarterly earnings data on Monday, October 29th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.01). The business had revenue of $14.22 million during the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. As a group, analysts forecast that Nuvectra will post -3.44 EPS for the current year.

In related news, President Joseph Paul Hanchin sold 1,250 shares of the company’s stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $20.43, for a total value of $25,537.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 4.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. lifted its position in Nuvectra by 0.6% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 432,040 shares of the company’s stock valued at $9,496,000 after acquiring an additional 2,464 shares in the last quarter. First Manhattan Co. purchased a new stake in Nuvectra during the 2nd quarter valued at $102,000. Metropolitan Life Insurance Co. NY purchased a new stake in Nuvectra during the 2nd quarter valued at $105,000. Essex Investment Management Co. LLC raised its stake in Nuvectra by 3.8% during the 3rd quarter. Essex Investment Management Co. LLC now owns 183,418 shares of the company’s stock valued at $4,032,000 after buying an additional 6,729 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new stake in Nuvectra during the 2nd quarter valued at $148,000. 78.21% of the stock is currently owned by institutional investors and hedge funds.

Nuvectra Company Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

Recommended Story: What is a Fiduciary?

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.